WHO recommends use of first typhoid conjugate vaccine

Geneva, Switzerland – April 3, 2018 – The World Health Organization (WHO) recommends the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in typhoid-endemic countries. This new policy will help ensure access to typhoid vaccination in communities most impacted by the disease, which is responsible for nearly 12 million infections and between 128,000 and 161,000 deaths a year.

WHO issued these recommendations following a review of evidence on TCVs by WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization in October 2017. The group considered data on vaccine safety, efficacy, feasibility, and affordability, as well as growing rates of drug-resistant typhoid. Based on these discussions, SAGE recommended TCVs for children over the age of six months. These recommendations were accepted and reported in the WHO updated position paper on typhoid vaccines in the Weekly Epidemiological Report published on March 30, 2018.

“Studies have shown that the typhoid conjugate vaccine is safe, effective, and can provide protection for infants and children under two years of age, unlike the previously available typhoid vaccines,” said Dr. Adwoa Bentsi-Enchill, medical officer of the Department of Immunization, Vaccines and Biologicals at WHO. “The recommendation for the typhoid conjugate vaccine to be included in routine immunization programs will help pave the way for national authorities to introduce this vaccine in countries where they are needed most.”

The updated WHO position paper emphasizes the importance of using typhoid vaccines to control endemic and epidemic typhoid, and recommends that typhoid-endemic countries introduce TCV in a single dose for infants and children over the age of six months. Where feasible, vaccine introduction should be accompanied by catch-up vaccination campaigns for children up to 15 years of age in endemic countries. Additionally, the position paper recommended prioritizing TCV introduction in countries with the highest burden of disease or a growing burden of drug-resistant typhoid. TCV was also recommended as a response to confirmed typhoid outbreaks and for specific groups of people at high risk or with high transmission potential, including travelers from non-endemic to endemic areas.

Compared to earlier typhoid vaccines, TCV provides longer-lasting protection, requires fewer doses and is suitable for children under two years of age. These advantages allow delivery through routine infant immunization programs and better protection of young children.

“Vaccines are one of the best investments we can make to give every child a healthy start and this WHO recommendation is an important step toward our goal of addressing the high burden of typhoid in children. For too long, typhoid, which invariably affects the world’s poorest communities, has been neglected in efforts to improve global health,” said Dr. Anita Zaidi, director of the Vaccine Development and Surveillance, and Enteric and Diarrheal Diseases teams at the Bill & Melinda Gates Foundation. “With this new vaccine, countries will finally be able to protect millions of children who are most vulnerable to this deadly disease.”

Expanding coverage of TCV through routine immunization would reduce disease incidence and potentially decrease the need for antibiotics – two priorities of the effort to stem the development and spread of drug-resistant typhoid. WHO highlighted TCV as a critical tool to slow further emergence of drug-resistant typhoid strains and ultimately save lives.

“Typhoid fever is a familiar public health problem in many developing countries where rapid urbanization and an alarming increase of multidrug-resistant typhoid are creating an urgent need to focus on prevention,” said Dr. Kathy Neuzil, director of the Center for Vaccine Development at the University of Maryland School of Medicine. “These WHO recommendations are a vital step to delivering TCVs to those who need them most and relieving the pressure on public health systems tasked with treating drug-resistant strains.”

The first TCV, Typbar TCV®, achieved WHO prequalification in December 2017, a critical step allowing WHO, the United Nations Children’s Fund, and other United Nations procurement agencies to purchase the vaccine. Prequalification also serves as an endorsement of quality, efficacy, and safety for countries interested in adopting the vaccine. It enables eligible countries to receive funding assistance from Gavi, the Vaccine Alliance, which recently approved US$ 85 million to support the introduction of TCVs. Gavi-supported countries can now apply; introduction of the vaccine is anticipated by mid-2019.

“The typhoid conjugate vaccine will not only save lives, but also bolster the fight against anti-microbial drug-resistance,” said Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Expanding vaccine coverage will play an important role in reducing illnesses and deaths from typhoid. Gavi is looking forward to working with countries to support the introduction of this safe and effective vaccine.”

Typhoid disproportionally impacts young children and marginalized populations in much of Asia, sub-Saharan Africa, and parts of Latin America and the Middle East that often have outdated, inadequate, or unsafe water and sanitation systems. With supportive global and financial policies in place, typhoid vaccines, in addition to water, sanitation, and hygiene interventions, can reach those who need them most and reduce the burden of typhoid fever.

“With the release of this revised position paper and the opportunity for countries to apply for Gavi support of TCV introduction, we now have the global policy in place to roll out TCVs,” said Dr. Denise Garrett, director of the Coalition against Typhoid and vice president of Typhoid Programs at the Sabin Vaccine Institute. “Effectively preventing typhoid and the suffering it causes is a reality within our reach.”


About the Sabin Vaccine Institute

The Sabin Vaccine Institute, which serves as the secretariat of the Coalition against Typhoid, is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit http://www.sabin.org.

The Sabin Vaccine Institute’s Coalition against Typhoid has led efforts to prevent typhoid and other invasive salmonelloses through research, education, and advocacy. In October 2017, the Coalition joined forces with the Typhoid Vaccine Acceleration Consortium (TyVAC) to Take on Typhoid. Together, the Coalition and TyVAC are working to focus attention on typhoid and the need for typhoid conjugate vaccines, and improved water, sanitation, and hygiene interventions to reduce the burden and impact of typhoid fever. Additional data on typhoid conjugate vaccine effectiveness will be generated by TyVAC studies underway in Bangladesh, Nepal, and Malawi.


About the Typhoid Vaccine Acceleration Consortium

The Typhoid Vaccine Acceleration Consortium (TyVAC) is a partnership between the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an international nonprofit organization. TyVAC aims to accelerate the introduction of new typhoid conjugate vaccines (TCVs) as part of an integrated approach to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance.

TyVAC employs a multidisciplinary approach, working with global and local partners to accelerate the introduction of TCVs in low-income countries and facilitate access to typhoid vaccines as part of an integrated prevention plan that also includes improved water, sanitation, and hygiene. We work to ensure that typhoid prevention and control are global health priorities and that stakeholders and decision-makers have the data and tools they need to make evidence-based decisions for TCV introduction. For more information, visit http://www.medschool.umaryland.edu/CVD/TyVAC/.


Media Contacts:  

Hannah Bassett, Communications Associate, Sabin Vaccine Institute, +1 (202) 621-1691, hannah.bassett@sabin.org

Leslie Jamka, Manager, Media Relations, Center for Vaccine Development, +1 (410) 706-3987, ljamka@som.umaryland.edu


Statements of support for WHO’s recommendation on typhoid conjugate vaccine